CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

A Randomized single blind controlled clinical trial on safety and efficacy of a Unani formulation (Itrifal-e-Sagheer) in dyslipidemia

  • Alam, Sazid (Department of Moalajat (Medicine), Sufia Unani medical college hospital and research center) ;
  • Alam, MD Anzar (Department of Moalajat, National Institute of Unani medicine) ;
  • Quamri, MA (Department of Moalajat, National Institute of Unani medicine) ;
  • Sofi, Ghulamuddin (Department of Ilmul Advia, National Institute of Unani medicine) ;
  • Khan, Mohd. Qudratullah (Luqman Unani medical college hospital and research center) ;
  • Ansari, Shabnam (Department of biotechnology, Faculty of natural sciences, Jamia Millia Islamia)
  • Received : 2019.12.25
  • Accepted : 2020.01.14
  • Published : 2020.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Aim:'Itrifal-e-Sagheer', a compound Unani formulation has been indicated in disease conditions simulating dyslipidemia. The present study was done to substantiate the efficacy of 'Itrifal-e-Sagheer' in dyslipidemia on scientific parameters. Materials and methods: A randomized, single blind, controlled, clinical trial was carried out on 30 patients of dyslipidemia who were randomly allocated into test (n = 15) or control (n = 15) groups. The test drug, Itrifal-e-Sagheer and control drug, Abana® were given to respective group for 45 days along with lifestyle modification. Results: The test drug significantly alleviated the symptoms of subjective parameters (palpitation, breathlessness and weight gain) (p<0.05). There was statistically significant reduction in lipid profile of the patients in test group (p<0.05) than control drug treatment. Conclusion: The study evidenced that Itrifal-e-Sagheer is potentially effective and safe in the treatment of dyslipidemia. However, a multicentric study with robust study design is required to generalize the results.

Keywords

References

  1. Ahmad SI. Al Umoor Al Tabi'yah. New Delhi: CCRUM; 1980. P. 162-7, 174-5.
  2. Ajay RS, Sivakumar K, Sujatha K. Prevalence of dyslipidaemia in South Indian adults: an urban-rural comparison. Int J Community Med Public Health. 2016;3(8):2201-10.
  3. Anonymous. The Unani Pharmacopoeia of India. Part I, Volume I. New Delhi: Ministry of AYUSH; 2007. P. 5-6, 17-18, 32-33.
  4. Bag A, Bhattacharyya SK, Chattopadhyay. The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac J Trop Biomed. 2013;3(3):244-252. https://doi.org/10.1016/S2221-1691(13)60059-3
  5. Baitar I. Al Jami Li Mufradat Al Advia wa al Aghziya. Vol 1, 4. New Delhi: Central Council for Research in Unani Medicine; 2000. P. 129-131, 198-9, 276-7, 313-5, 436-9.
  6. Baliga MS. Triphala, ayurvedic formulation for treating and preventing cancer: a review. J Altern Complement Med. 2010;16(12):1301-08. https://doi.org/10.1089/acm.2009.0633
  7. Bolli P. Treatment of dyslipidaemia: The problem of reaching the goal. Atherosclerosis. 2014;236:142-3. https://doi.org/10.1016/j.atherosclerosis.2014.06.003
  8. Brunton LL. Goodman and Gilman's the pharmacological basis of therapeutics. 10th edn. USA: McGraw Hill. 2001. P. 984-95.
  9. Ghani N. Khazainul Advia. 2nd edn. New Delhi: Idara Kitab us Shifa; 2008. P. 187-189, 421-422, 1352-1354.
  10. Gilani HA, Khana A, Tuba Ali T, Ajmal S. Mechanisms underlying the antispasmodic and bronchodilatory properties of Terminalia bellerica fruit. J. of Ethnopharmacology. 2008;116:528-538. https://doi.org/10.1016/j.jep.2008.01.006
  11. Kabeeruddin HM. Biyaz Kabir. Vol 2. Hyderabad: Hikmat Book Depo, Hyde; YNM. P. 5
  12. Kabiruddin A. Kulliyate Qanun. New Delhi: Eajaz Publication; 2006. P. 222.
  13. Kamali SH, Khalaj AR, Ranjbar SH, Esfehani MM, Kamalinejad M, Soheil O, Kamali SA. Efficacy of 'Itrifal Saghir', a combination of three medicinal plants in the treatment of obesity; A randomized controlled trial. DARU Journal of Pharmaceutical Sciences. 2012;20(1):1-8. https://doi.org/10.1186/1560-8115-20-1
  14. Majoosi AIA. Kamilus Sanaa. Vol. 1, 2. (Urdu translation by Gulam Hasnain Kantoori). New Delhi: Idara Kitab us Shifa;2010. P. 52-3, 102-4, 336-7, 441.
  15. Park K. Park textbook of preventive and social medicine.24th edn. Jabalpur: M/s Banarsidas Bhanot Publishers; 2017. P. 410-19.
  16. Rajak S, Banerjee SK, Sood S, Dinda AK, Gupta YK, Gupta SK. Emblica officinalis causes myocardial adaptation and protects against oxidative stress in ischemic-reperfusion injury in rats. Phytotherapy research. 2004;18(1):54-60. https://doi.org/10.1002/ptr.1367
  17. Shah SN. API Text book of Medicine. 9th edn, Vol 2. Mumbai: The Association of physicians of India; 2012. P.1235-39.
  18. Singh RB, Niaz MA, Rastogi V, Singh N, Postiglione A, Rastogi SS. Hypolipidemic and antioxidant effects of fenugreek seeds and triphala as adjuncts to dietary therapy in patients with mild to moderate hypercholesterolemia. Perfusion. 1998;11(3):124.
  19. Suchalatha S, Shyamala Devi CS. Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol. Indian J Exp Biol. 2004; 42(2):174-178
  20. Tariq M, Hussain SJ, Asif M, Jahan M. Protective effect of fruit extracts of Emblica officinalis (Gaertn). And Terminalia bellerica (Roxb.) in experimental myocardial necrosis in rats. Indian J Exp Biol. 1977;15(6):485-486.
  21. Tripathi KD. Essentials of medical pharmacology.7th edn. New Delhi: Jaypee Brother Medical Publication; 2013. P. 634-44.
  22. Varady KA, Jones PJ. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr. 2005;135(8):1829-35. https://doi.org/10.1093/jn/135.8.1829
  23. Yang MH, Vasquez Y, Ali Z, et al. Constituents from Terminalia species increase PPAR alpha and PPAR gamma levels and stimulate glucose uptake without enhancing adipocyte differentiation. J Ethnopharmacol. 2013;149:490-498. https://doi.org/10.1016/j.jep.2013.07.003